Publications
Publications Co-Authored by Lundbeck Scientists
Our commitment to science is reflected in our track record of publications. Here are the most recent publications co-authored by Lundbeck scientists.
| Article | Product | Authors | Publication links | Year | Journal |
| 6-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension |
Droxidopa | Francois C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, Quillen A, Cannon J, Padilla C, Kymes S, Yue B | Read publication | 2019 | Movement Disorders Clinical Practice |
| A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder | Brexpiprazole | Hobart M, Zhang P, Brewer C, Hefting N | Read publication | 2019 | Journal of Clinical Psychopharmacology |
| A new principal stratum estimand investigating the treatment effect in patients who would comply, if treated with a specific treatment | Brexpiprazole | Groes Larsen K, Krog Josiassen M | Read publication | 2019 | Statistics in Biopharmaceutical Research |
| A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder | Vortioxetine | Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I | Read publication | 2019 | Psychiatry and Clinical Neurosciences |
| A Systematic Literature Review Identifying Associations Between Outcomes and Quality of Life (QoL) or Health Care Resource Utilisation (HCRU) in Schizophrenia | Lu AF35700 | Germain N, Weatherall J, Kymes S, Löf E, Jakubowska A, François C | Read publication | 2019 | Journal of Medical Economics |
| Adapting the goal attainment approach for major depressive disorder | Vortioxetine | McCue M, Parikh S, Mucha L, Sarkey S, Cao C, Eramo A, Opler M, Lind B, Francois C | Read publication | 2019 | Neurology and Therapy |
| Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course | Brexpiprazole | Anatchkova M, Brooks A, Swett L, Hartry A, Duffy RA, Baker RA, Hammer-Helmich L, Sanon Aigbogun M | Read publication | 2019 | International Psychogeriatrics |
| Anti-tau antibody-mediated clearance in mouse microglia cultures requires Fcγ-receptor interaction and functional lysosomes | AF87908 Tau | Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT | Read publication | 2019 | Scientific Reports |
| Assessment of current clinical practices for major depression in Japan using a web-based questionnaire | Vortioxetine | Hori H, Kentaro Y | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats | Brexpiprazole | Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H Kurahashi N, Kikuchi T, Futamura T | Read publication | 2019 | Neuropsychopharmacology Reports |
| Burden of Care for Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes and Perceptions | Lu AF35700 | Velligan D, Brain C, Bouérat Duvold L, Agid O, | Read publication | 2019 | Frontiers in Psychiatry |
| Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine | Vortioxetine | Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Chokka P, Proulx J, Bougie J |
Read publication | 2019 | CNS Spectrums |
| Characteristics, Burden and Pharmacotherapy of Treatment-Resistant Schizophrenia: Results From a Survey of 204 US Psychiatrists | Lu AF35700 | Correll CU, Brevig T, Brain C | Read publication | 2019 | BMC Psychiatry |
| Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia | Lu AF35700 | Agid O, Baldwin M, Correll C, Howes O, Kane J, Lindenmayer JP, Marder S, Olfson M, Potkin S | Read publication | 2019 | Journal of Clinical Psychiatry |
| Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram | Vortioxetine | Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton | Read publication | 2019 | CNS Spectrums |
| Cognitive symptoms in major depressive disorder: Associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China | Vortioxetine | Wang G, Si T-M, Li L-J, Fang Y-R, Wang C-X, Wang L-N, Tan K H X, Ettrup A; Eriksen F H-L, Luo S, Ge L | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Comparisons of Global Tests on Intersection Hypotheses and Their Application in Matched Parallel Gatekeeping Procedures | Brexpiprazole | Ouyang J, Zhang P, Carroll KJ, Lee J, Koch G | Read publication | 2019 | Journal of Biopharmaceutical Statistics |
| Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases | Vortioxetine | Touya M, Lamy FX, Tanaescu A, Saragoussi D, Francois C, Wade A, Llorca PM, Lancon C, Falissard B | Read publication | 2019 | Journal of Market Access & Health Policy |
| Development of a Classifier to Identify Patients with Probable Lennox–Gastaut Syndrome in Health Insurance Claims Databases Via Random Forest Methodology | Clobazam | Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J | Read publication | 2019 | Current Medical Research & Opinion |
| Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression | Vortioxetine | Baune B, Christensen MC | Read publication | 2019 | Frontiers in Psychiatry |
| Drug-Drug Interactions With Concomitant Clobazam and Cannabidiol Usage in Refractory Seizures | Clobazam | Tolbert D, Klein P, Gidal B | Read publication | 2019 | Epilepsy & Behavior |
| Early Initiation of Long-Acting Injectable Antipsychotic Treatment is Associated with Lower Hospitalization Rates and Healthcare Costs in Patients with Schizophrenia: Real-World Evidence From US Claims Data | Aripiprazole | Munday J, Broder MS, Chang E, Hartry A, Yan TJ, Greene M |
Read publication |
2019 | Current Medical Research & Opinion |
| Economic burden of relapse/recurrence in patients with major depressive disorder | Vortioxetine | Gauthier G, Mucha L, Shi S, Guerin A | Read publication | 2019 | Journal of Drug Assessment |
| Effect of brexpiprazole on agitation and hostility in patients with acute schizophrenia | Brexpiprazole | Citrome L, Ouyang J, Meehan SR, Baker RA, Weiss C | Read publication | 2019 | Journal of Clinical Psychopharmacology |
| Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain | Vortioxetine | Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ | Read publication | 2019 | Neuropsychopharmacology |
| Effects of vortioxetine and escitalopram on electroencephalographic recordings – A randomized, crossover trial in healthy males | Vortioxetine | Nissen TD, Laursen B, Viardot G, l´Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM | Read publication | 2019 | Neuroscience |
| Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis | Vortioxetine | Jacobson W, Harvey P, Zhong W, Nomikos G, Olsen CK, Christensen M | Read publication | 2019 | Current Medical Research & Opinion |
| Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies | Brexpiprazole | Thase M, Hobart M, Zhang P, Weiss C, Meehan SR | Read publication | 2019 | Expert Opinion on Pharmacotherapy |
| Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials | Brexpiprazole | Grossberg G, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade R, Cummings J | Read publication | 2019 | American Journal of Geriatric Psychiatry |
| Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma | Vortioxetine | Christensen MC, Florea I, Loft H, McIntyre RS | Read publication | 2019 | Journal of Affective Disorders |
| Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial | Eptinezumab | Dodick DW, Lipton RB, Silberstein S, Goadsby P4, Biondi D, Hirman J, Cady R, Smith J | Read publication | 2019 | Cephalalgia |
| Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists | Lu AF35700 | Correll CU, Brevig T, Brain C | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Health-related quality of life outcomes, economic burden and cost associated among diagnosed and undiagnosed depression patients in Japan | Vortioxetine | Yamabe K, Liebert R, Flores N | Read publication | 2019 | ClinicoEconomics and Outcomes Research |
| Identifying and Characterizing Treatment-Resistant Schizophrenia in Observational Database Studies | Lu AF35700 | Jonsson L, Simonsen J, Brain C, Kymes S, Watson L | Read publication | 2019 | International Journal of Methods in Psychiatric Research |
| Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 2-week, randomized, double-blind, placebo-controlled study | Vortioxetine | Vieta E, Florea I, Schmidt S N, Areberg J, Ettrup A | Read publication | 2019 | International Clinical Psychopharmacology |
| Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder: results from the AtWoRC study | Vortioxetine | Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A | Read publication | 2019 | CNS Spectrums |
| Management of Coexistent Neurogenic Orthostatic Hypotension and Supine Hypertension | Droxidopa | Cannom D | Read publication | 2019 | Journal of Clinical Hypertension |
| Management of Depression in Adolescents in Japan | Escitalopram | Saito T, Reines E, Florea I, Dalsgaard M | Read publication | 2019 | Journal of Child and Adolescent Psychopharmacology |
| Medication adherence, health service use, and costs in patients with major depressive disorder initiating adjunctive antipsychotic treatment | Brexpiprazole | Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I | Read publication | 2019 | Clinical Therapeutics |
| Neurogenic Orthostatic Hypotension: A Nonmotor Symptom of Parkinson Disease | Droxidopa | Low P, Cutsforth-Gregory J | Read publication | 2019 | Neurology and Therapy |
| Open-label, Multicenter, Phase 3 Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease | Idalopirdine | Frölich L, Alireza A, Ballard C, Tariot P, Molinuevo JL, Boneva N, Geist M, Raket L, Cummings J | Read publication | 2019 | Journal of Alzheimer's Disease |
| Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls | Droxidopa | LeWitt P, Kymes S, Hauser R | Read publication | 2019 | Aging and Disease |
| Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial | Vortioxetine | Jacobsen P, Zhong W, Nomikos G, Clayton A | Read publication | 2019 | The Journal of Sexual Medicine |
| Patient attitudes towards and goals for MDD treatment: A survey study | Vortioxetine | McNaughton E, Granskie J, Curran C, Opler M, Sarkey S, Mucha L, Eramo A, Francois C, Webber-Lind B, McCue M | Read publication | 2019 | Patient Preference and Adherence |
| Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study | Vortioxetine | Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Pharmacokinetics and safety of vortioxetine in the Chinese population | Vortioxetine | Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A | Read publication | 2019 | Advances in Therapy |
| Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide | Eptinezumab | Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF | Read publication | 2019 | Journal of Pharmacology and Experimental Therapeutics |
| Pharmacometrics of Clobazam in Pediatrics: Prediction of Effective Clobazam Doses for Dravet Syndrome | Clobazam | Tolbert D, Chu H-M, Ette EI | Read publication | 2019 | Epilepsy Research |
| Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis | Vortioxetine | Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F | Read publication | 2019 | British Journal of Clinical Pharmacology |
| Psychometric validation of Japanese version of Alcohol Quality of Life Scale (AQoLS) in the treatment of patients with alcohol use disorder – a non-interventional, prospective, longitudinal, multi-site cohort study | Nalmefene | Higuchi S, Moriguchi Y, Tan KHX | Read publication | 2019 | Quality of Life Research |
| Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study | Aripiprazole | Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A | Read publication | 2019 | BMC Psychiatry |
| Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: cross sectional analysis of baseline data from PERFORM-J | Vortioxetine | Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan K, Hammer-Helmich L, Fernandez J | Read publication | 2019 | Journal of Affective Disorders |
| Results and validation of an index to measure health state of patients with depression in automated healthcare databases | Vortioxetine | Lamy FX, Falissard B, Francois C, Lancon C, Llorca PM, Tanaescu A, Touya M, Verpillat P, Wade A, Saragoussi D | Read publication | 2019 | Journal of Market Access & Health Policy |
| Results of a Real-World Study of Vortioxetine in Patients with Major Depressive Disorder in South East Asia (REVIDA): Subgroup Analysis of Malaysian Patients | Vortioxetine | Chin CN, Azhar, Au YKC, Chong MSwee Woon, Yen TH, Yeoh BBD, Yap CH, Ku RKA, Keira JH | Read publication | 2019 | Malaysian Journal of Psychiatry |
| Role of Nurses and Nurse Practitioners in the Recognition, Diagnosis, and Management of Neurogenic Orthostatic Hypotension | Droxidopa | Biswas D, Karabin B, Turner D | Read publication | 2019 | International Journal of General Medicine |
| Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. | Vortioxetine | Mahableshwarkar A, Jacobsen P, Affinito J, Reines E, Xu J, Nomikos G | Read publication | 2019 | CNS Spectrums |
| Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies | Aripiprazole | Madera JJ, Such P, Zhao C, Baker RA | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| The effect of aripiprazole once monthly on personal and social functioning: Post hoc analyses of acute and long-term studies | Aripiprazole | Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| The patient perspective on cognitive symptoms in major depressive disorder: a retrospective database and prospective survey analysis | Vortioxetine | Chiauzzi E, Drahos J, Sarkey S, Curran C, Wang V, Tomori D | Read publication | 2019 | Journal of Participatory Medicine |
| Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine | Vortioxetine | Nierenberg AA, Loft H, Olsen CK | Read publication | 2019 | Journal of Affective Disorders |
| Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient With Cardiovascular Disease and Parkinson Disease: A Case Report | Droxidopa | McCullough P | Read publication | 2019 | Cardiology and Therapy |
| Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis | Brexpiprazole | Sanon Aigbogun M, Stellhorn R, Hartry A, Baker RA, Fillit H | Read publication | 2019 | BMC Neurology |
| Use of Droxidopa for the Long-Term Treatment of Neurogenic Orthostatic Hypotension | Droxidopa | Hewitt LA, Raj S | Read publication | 2019 | European Heart Journal |
| Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment | Aripiprazole | Madera JJ, Such P, Zhang P, Baker RA, Grande I | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder | Vortioxetine | Murthy V, Xu R, Zhong W, Harvey P | Read publication | 2019 | Journal of Affective Disorders |
| Utility of Autonomic Testing for the Efficient Diagnosis and Effective Pharmacologic Management of Neurogenic Orthostatic Hypotension | Droxidopa | Suleman, A; Bin Alam, S; Almardini W | Read publication | 2019 | BMJ Case Reports |
| Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized double-blind, placebo-controlled proof-of-concept study | Vortioxetine | Biederman J, Lindsten A, Sluth L B, Petersen M L, Ettrup A, Eriksen H-L F, Fava M | Read publication | 2019 | Journal of Psychopharmacology |
| Wearable Technology for High-Frequency Cognitive and Mood Assessment in Major Depressive Disorder: Longitudinal Observational Study. | Vortioxetine | Cormack F, McCue M, Taptiklis N, Skirrow C, Glazer E, Panagopoulos E, van Schaik TA, Fehnert B, King J, Barnett JH | Read publication | 2019 | JMIR Mental Health |